Cargando…

Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection

OBJECTIVE: Inflammation plays a crucial role in tumorigenesis and progression. Our purpose was to investigate the prognostic value of neutrophil-to-lymphocyte ratio (NLR), systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII), and develop a nomogram to predict the...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yu-Jia, Qian, Li-Qiang, Ding, Zheng-Ping, Luo, Qing-Quan, Zhao, Heng, Xia, Wu-Yan, Fu, Yuan-Yuan, Feng, Wen, Zhang, Qin, Yu, Wen, Cai, Xu-Wei, Fu, Xiao-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440980/
https://www.ncbi.nlm.nih.gov/pubmed/34540678
http://dx.doi.org/10.3389/fonc.2021.711206
_version_ 1783752781896613888
author Shen, Yu-Jia
Qian, Li-Qiang
Ding, Zheng-Ping
Luo, Qing-Quan
Zhao, Heng
Xia, Wu-Yan
Fu, Yuan-Yuan
Feng, Wen
Zhang, Qin
Yu, Wen
Cai, Xu-Wei
Fu, Xiao-Long
author_facet Shen, Yu-Jia
Qian, Li-Qiang
Ding, Zheng-Ping
Luo, Qing-Quan
Zhao, Heng
Xia, Wu-Yan
Fu, Yuan-Yuan
Feng, Wen
Zhang, Qin
Yu, Wen
Cai, Xu-Wei
Fu, Xiao-Long
author_sort Shen, Yu-Jia
collection PubMed
description OBJECTIVE: Inflammation plays a crucial role in tumorigenesis and progression. Our purpose was to investigate the prognostic value of neutrophil-to-lymphocyte ratio (NLR), systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII), and develop a nomogram to predict the cancer-specific survival (CSS) and disease-free survival (DFS) of stage I lung adenocarcinoma patients. METHODS: 1431 patients undergoing surgical resection with pathologically confirmed stage I lung adenocarcinoma were reviewed. The optimal cut-off values for NLR, SII, and SIRI were defined by the receiver operating characteristic (ROC) curve. Cox proportional hazards regression analyses were performed to recognize factors significantly correlated with CSS and DFS to construct the nomogram. The value of adjuvant chemotherapy on model-defined high-risk and low-risk patients was further explored. RESULTS: The cohort had a median follow-up time of 63 months. Multivariate analysis revealed that higher NLR (≥2.606), higher SIRI (≥0.705), higher SII (≥580.671), later T stage, histological pattern with solid or micropapillary components and radiologic features with solid nodules were significantly associated with worse CSS and DFS. The concordance index (C-index) of the nomogram established by all these factors was higher than that of the TNM staging system both in CSS (validation set 0.778 vs 0.652) and DFS (validation set 0.758 vs 0.695). Furthermore, the value of the established nomogram on risk stratification in stage I lung adenocarcinoma patients was validated. CONCLUSIONS: Higher NLR, SII and SIRI pretreatment were associated with worse survival outcomes. A practical nomogram based on these three inflammatory biomarkers may help clinicians to precisely stratify stage I lung adenocarcinoma patients into high- and low-risk and implement individualized treatment.
format Online
Article
Text
id pubmed-8440980
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84409802021-09-16 Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection Shen, Yu-Jia Qian, Li-Qiang Ding, Zheng-Ping Luo, Qing-Quan Zhao, Heng Xia, Wu-Yan Fu, Yuan-Yuan Feng, Wen Zhang, Qin Yu, Wen Cai, Xu-Wei Fu, Xiao-Long Front Oncol Oncology OBJECTIVE: Inflammation plays a crucial role in tumorigenesis and progression. Our purpose was to investigate the prognostic value of neutrophil-to-lymphocyte ratio (NLR), systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII), and develop a nomogram to predict the cancer-specific survival (CSS) and disease-free survival (DFS) of stage I lung adenocarcinoma patients. METHODS: 1431 patients undergoing surgical resection with pathologically confirmed stage I lung adenocarcinoma were reviewed. The optimal cut-off values for NLR, SII, and SIRI were defined by the receiver operating characteristic (ROC) curve. Cox proportional hazards regression analyses were performed to recognize factors significantly correlated with CSS and DFS to construct the nomogram. The value of adjuvant chemotherapy on model-defined high-risk and low-risk patients was further explored. RESULTS: The cohort had a median follow-up time of 63 months. Multivariate analysis revealed that higher NLR (≥2.606), higher SIRI (≥0.705), higher SII (≥580.671), later T stage, histological pattern with solid or micropapillary components and radiologic features with solid nodules were significantly associated with worse CSS and DFS. The concordance index (C-index) of the nomogram established by all these factors was higher than that of the TNM staging system both in CSS (validation set 0.778 vs 0.652) and DFS (validation set 0.758 vs 0.695). Furthermore, the value of the established nomogram on risk stratification in stage I lung adenocarcinoma patients was validated. CONCLUSIONS: Higher NLR, SII and SIRI pretreatment were associated with worse survival outcomes. A practical nomogram based on these three inflammatory biomarkers may help clinicians to precisely stratify stage I lung adenocarcinoma patients into high- and low-risk and implement individualized treatment. Frontiers Media S.A. 2021-09-01 /pmc/articles/PMC8440980/ /pubmed/34540678 http://dx.doi.org/10.3389/fonc.2021.711206 Text en Copyright © 2021 Shen, Qian, Ding, Luo, Zhao, Xia, Fu, Feng, Zhang, Yu, Cai and Fu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Shen, Yu-Jia
Qian, Li-Qiang
Ding, Zheng-Ping
Luo, Qing-Quan
Zhao, Heng
Xia, Wu-Yan
Fu, Yuan-Yuan
Feng, Wen
Zhang, Qin
Yu, Wen
Cai, Xu-Wei
Fu, Xiao-Long
Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection
title Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection
title_full Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection
title_fullStr Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection
title_full_unstemmed Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection
title_short Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection
title_sort prognostic value of inflammatory biomarkers in patients with stage i lung adenocarcinoma treated with surgical dissection
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440980/
https://www.ncbi.nlm.nih.gov/pubmed/34540678
http://dx.doi.org/10.3389/fonc.2021.711206
work_keys_str_mv AT shenyujia prognosticvalueofinflammatorybiomarkersinpatientswithstageilungadenocarcinomatreatedwithsurgicaldissection
AT qianliqiang prognosticvalueofinflammatorybiomarkersinpatientswithstageilungadenocarcinomatreatedwithsurgicaldissection
AT dingzhengping prognosticvalueofinflammatorybiomarkersinpatientswithstageilungadenocarcinomatreatedwithsurgicaldissection
AT luoqingquan prognosticvalueofinflammatorybiomarkersinpatientswithstageilungadenocarcinomatreatedwithsurgicaldissection
AT zhaoheng prognosticvalueofinflammatorybiomarkersinpatientswithstageilungadenocarcinomatreatedwithsurgicaldissection
AT xiawuyan prognosticvalueofinflammatorybiomarkersinpatientswithstageilungadenocarcinomatreatedwithsurgicaldissection
AT fuyuanyuan prognosticvalueofinflammatorybiomarkersinpatientswithstageilungadenocarcinomatreatedwithsurgicaldissection
AT fengwen prognosticvalueofinflammatorybiomarkersinpatientswithstageilungadenocarcinomatreatedwithsurgicaldissection
AT zhangqin prognosticvalueofinflammatorybiomarkersinpatientswithstageilungadenocarcinomatreatedwithsurgicaldissection
AT yuwen prognosticvalueofinflammatorybiomarkersinpatientswithstageilungadenocarcinomatreatedwithsurgicaldissection
AT caixuwei prognosticvalueofinflammatorybiomarkersinpatientswithstageilungadenocarcinomatreatedwithsurgicaldissection
AT fuxiaolong prognosticvalueofinflammatorybiomarkersinpatientswithstageilungadenocarcinomatreatedwithsurgicaldissection